AU2022397307A1 - Cleavable radioligands for targeting cell surface receptors and uses thereof - Google Patents

Cleavable radioligands for targeting cell surface receptors and uses thereof Download PDF

Info

Publication number
AU2022397307A1
AU2022397307A1 AU2022397307A AU2022397307A AU2022397307A1 AU 2022397307 A1 AU2022397307 A1 AU 2022397307A1 AU 2022397307 A AU2022397307 A AU 2022397307A AU 2022397307 A AU2022397307 A AU 2022397307A AU 2022397307 A1 AU2022397307 A1 AU 2022397307A1
Authority
AU
Australia
Prior art keywords
compound
cleavable linker
cleavable
nci
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022397307A
Other languages
English (en)
Inventor
Alla Darwish
Fa Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Full Life Technologies Uk Ltd
Original Assignee
Full Life Tech Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Full Life Tech Uk Ltd filed Critical Full Life Tech Uk Ltd
Publication of AU2022397307A1 publication Critical patent/AU2022397307A1/en
Assigned to FULL-LIFE TECHNOLOGIES UK LIMITED reassignment FULL-LIFE TECHNOLOGIES UK LIMITED Request for Assignment Assignors: FULL-LIFE TECHNOLOGIES HK LIMITED
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022397307A 2021-11-26 2022-11-23 Cleavable radioligands for targeting cell surface receptors and uses thereof Pending AU2022397307A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163283361P 2021-11-26 2021-11-26
US63/283,361 2021-11-26
PCT/US2022/050952 WO2023097038A1 (en) 2021-11-26 2022-11-23 Cleavable radioligands for targeting cell surface receptors and uses thereof

Publications (1)

Publication Number Publication Date
AU2022397307A1 true AU2022397307A1 (en) 2024-06-06

Family

ID=86540347

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022397307A Pending AU2022397307A1 (en) 2021-11-26 2022-11-23 Cleavable radioligands for targeting cell surface receptors and uses thereof

Country Status (10)

Country Link
US (2) US12214059B2 (https=)
EP (1) EP4436979A1 (https=)
JP (1) JP2024542592A (https=)
KR (1) KR20240121775A (https=)
CN (1) CN118451091A (https=)
AU (1) AU2022397307A1 (https=)
CA (1) CA3238734A1 (https=)
CL (1) CL2024001560A1 (https=)
MX (1) MX2024005950A (https=)
WO (1) WO2023097038A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
AU2022397307A1 (en) 2021-11-26 2024-06-06 Full-Life Technologies Uk Limited Cleavable radioligands for targeting cell surface receptors and uses thereof
WO2024126687A1 (en) * 2022-12-16 2024-06-20 Silence Therapeutics Gmbh Nucleic acids conjugated to an albumin binding moiety
CN121219017A (zh) * 2023-05-31 2025-12-26 辐联科技香港有限公司 缀合物及其用途
AU2024282578A1 (en) * 2023-05-31 2025-12-04 Full-Life Technologies Uk Limited Radioligands for targeting cell surface receptors and uses thereof
TW202540073A (zh) * 2023-11-30 2025-10-16 大陸商輻聯科技香港有限公司 靶向ｓｓｔｒ受體的放射性化合物及其用途
CN118240015B (zh) * 2024-03-21 2025-03-21 中国科学院近代物理研究所 一种针对脑胶质瘤的靶向多肽及放射性示踪剂
WO2026002208A1 (zh) * 2024-06-28 2026-01-02 思路迪生物医药(上海)有限公司 前列腺特异性膜抗原小分子抑制剂及其放射性核素配合物的制备及应用
WO2026080432A1 (en) * 2024-10-07 2026-04-16 Beth Israel Deaconess Medical Center, Inc. Dimeric p-selectin inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
CA2721183C (en) * 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
EP3609541A4 (en) * 2017-04-05 2021-04-07 Cornell University Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies
CA3060143A1 (en) * 2017-05-24 2018-11-29 Itm Isotopen Technologien Munchen Ag Novel psma-binding agents and uses thereof
AU2022397307A1 (en) 2021-11-26 2024-06-06 Full-Life Technologies Uk Limited Cleavable radioligands for targeting cell surface receptors and uses thereof

Also Published As

Publication number Publication date
JP2024542592A (ja) 2024-11-15
CN118451091A (zh) 2024-08-06
US20250099632A1 (en) 2025-03-27
EP4436979A1 (en) 2024-10-02
CL2024001560A1 (es) 2025-03-28
KR20240121775A (ko) 2024-08-09
CA3238734A1 (en) 2023-06-01
US20240382630A1 (en) 2024-11-21
MX2024005950A (es) 2024-08-06
WO2023097038A1 (en) 2023-06-01
US12214059B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
US12214059B2 (en) Cleavable radioligands for targeting cell surface receptors and uses thereof
RU2523531C2 (ru) Конъюгаты антагониста пептида аналога бомбезина
US8414864B2 (en) Gastrin releasing peptide compounds
EP2790732B1 (en) Clicked somatostatin conjugated analogs for biological applications
US20120065365A1 (en) Stable Radiopharmaceutical Compositions and Methods for Their Preparation
JP2009528286A (ja) 癌の画像化および処置
US12145926B2 (en) Compounds and radioligands for targeting neurotensin receptor and uses thereof
WO2025122615A1 (en) Enriched and stable radioligand therapy formulations and pharmaceutical compositions comprising same
WO2024083224A1 (en) Dual receptor targeting radioligands and uses thereof related applications
US20120178906A1 (en) Chelation of metals to thiol groups using in situ reduction of disulfide-containing compounds by phosphines
HK40111230A (zh) 用於靶向细胞表面受体的可裂解放射性配体及其用途
WO2024245421A1 (en) Radioligands for targeting cell surface receptors and uses thereof
JP2023506297A (ja) 癌のイメージングおよび治療のための修飾されたｇｒｐｒアンタゴニストペプチド
WO2025113628A1 (en) Sstr receptor targeting radio compounds and uses thereof
WO2024245407A1 (en) Conjugates and uses thereof
CA3258869A1 (en) ZWITTERIONIC COMPOUNDS AND THEIR USES

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: FULL-LIFE TECHNOLOGIES UK LIMITED

Free format text: FORMER APPLICANT(S): FULL-LIFE TECHNOLOGIES HK LIMITED